Zetia Cost in Massachusetts 2026: Prices, Insurance, Medicaid, and Savings Options

What Does Zetia Cost in Massachusetts in 2026?

Brand-name Zetia carries a manufacturer list price near $380 per month, but almost no Massachusetts patient actually pays that figure. Generic ezetimibe 10 mg, available from multiple manufacturers since 2017, costs roughly $15 per month at retail pharmacies across the state. Coupon platforms like GoodRx frequently bring that price to $9, $14 depending on the specific pharmacy.

The gap between list price and actual cash price exists because the patent on ezetimibe expired and generic competition compressed margins sharply. According to FDA Orange Book records, multiple manufacturers hold approved generic ezetimibe applications, keeping prices low [1]. The branded product still commands a premium only when a commercial insurer's formulary restricts the generic or when a patient has not yet switched.

Massachusetts retail chains including CVS, Walgreens, Rite Aid, and Stop and Shop generally stock generic ezetimibe. Independent pharmacies and warehouse clubs (Costco, BJ's) often price the 30-tablet supply even lower. Calling ahead to confirm inventory and price is always worthwhile because pharmacy acquisition costs vary by contract.

A 90-day supply through a mail-order pharmacy can reduce per-unit cost further. Patients enrolled in commercial plans that use CVS Caremark, Express Scripts, or OptumRx mail-order programs commonly pay $0, $30 for a 90-day generic ezetimibe fill, depending on their plan tier.

For clinical context, ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein in the intestinal brush border, reducing dietary and biliary cholesterol absorption by approximately 50% [2]. The FDA approved ezetimibe (Zetia) in 2002 for use as an adjunct to diet in adults with primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia [1].

Does Massachusetts Medicaid (MassHealth) Cover Zetia?

MassHealth covers ezetimibe, but prior authorization (PA) is required. The PA process asks prescribers to document that a statin is being used concurrently or is contraindicated, and that LDL-C remains above the target threshold despite statin therapy. Once approved, the member cost-share is typically $0, $3.65 per fill under standard MassHealth benefit rules.

The clinical rationale for the PA requirement comes directly from evidence. IMPROVE-IT (N=18,144), published in the New England Journal of Medicine in 2015, demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of cardiovascular death, major coronary events, or nonfatal stroke by an absolute 2.0 percentage points (32.7% vs. 34.7%, hazard ratio 0.936 to 95% CI 0.887, 0.988, P<0.001) over a median 6-year follow-up [3]. MassHealth uses this evidence to limit coverage to patients with established atherosclerotic cardiovascular disease (ASCVD) or very high LDL-C, consistent with the 2018 AHA/ACC Guideline on Management of Blood Cholesterol [4].

To obtain PA for a MassHealth member, the prescriber submits a clinical exception request through the MassHealth pharmacy portal or by fax. Most requests are reviewed within 3 business days. The approval period is typically 12 months, after which re-authorization is required. If the PA is denied, the member or prescriber may request a fair hearing through the Office of Medicaid.

MassHealth also covers the fixed-dose combination ezetimibe/simvastatin (Vytorin generic) under similar PA criteria. The standalone generic ezetimibe is generally preferred on formulary because its acquisition cost is lower.

Patients with both MassHealth and a Medicare Part D plan (dual eligibles) should check which payer is primary for outpatient drugs. Part D formularies differ by plan, and some dual-eligible plans place generic ezetimibe on Tier 1 with a $0 copay, making the MassHealth PA unnecessary.

Which Commercial Insurance Plans Cover Zetia in Massachusetts?

Most commercial plans in Massachusetts cover generic ezetimibe. Coverage varies significantly by plan design. The majority of plans place it on Tier 1 (preferred generic) or Tier 2 (non-preferred generic), with copays ranging from $0 to $45 per 30-day fill.

Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, and Mass General Brigham Health Plan all include generic ezetimibe on their standard formularies as of 2026. The specific tier and any required step therapy depend on the individual plan contract. Step therapy provisions sometimes require documentation of prior statin use or statin intolerance before ezetimibe is approved without additional cost.

The 2018 ACC/AHA guideline language is relevant here: "In patients with very high-risk ASCVD whose LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe to statin therapy" [4]. Insurers use this language as the basis for their medical necessity criteria.

Brand-name Zetia is almost universally placed on a higher tier or excluded from formulary now that generic ezetimibe is widely available. Patients who receive a brand prescription can typically ask their prescriber to authorize generic substitution, or the pharmacist can substitute automatically under Massachusetts generic substitution law unless the prescriber writes "no substitution" on the prescription.

If a commercial plan denies coverage, the appeals process under Massachusetts law requires the insurer to issue an expedited decision within 72 hours for urgent clinical situations. Non-urgent appeals must be resolved within 30 days. An independent external review is also available through the Massachusetts Division of Insurance if internal appeal fails.

What Is the Cheapest Way to Get Ezetimibe in Massachusetts?

The cheapest reliable route for most Massachusetts residents is generic ezetimibe purchased with a GoodRx or similar coupon at a large retail or warehouse pharmacy. Prices as low as $9 for a 30-tablet supply have been confirmed at Costco locations in the Boston metro area in 2026.

Options ranked from lowest to highest typical out-of-pocket cost:

1. 503A compounded ezetimibe through a licensed Massachusetts compounding pharmacy: $0, $10/month in some cases, particularly when prescribed alongside other compounded cardiovascular agents.
2. GoodRx or RxSaver coupon at a warehouse club (Costco, BJ's): $9, $12/month.
3. GoodRx coupon at a chain retail pharmacy: $9, $15/month.
4. MassHealth with approved PA: $0, $3.65/month.
5. Commercial insurance Tier 1: $0, $20/month.
6. Mark Cuban's Cost Plus Drugs (CostPlusDrugs.com): lists ezetimibe 10 mg at approximately $9 for 30 tablets plus a flat dispensing fee, available to Massachusetts residents who can receive mail-order prescriptions [5].
7. Patient assistance programs for low-income uninsured patients: Merck's Patient Assistance Program (PAP) provides Zetia at no cost to qualifying patients earning below 400% of the federal poverty level.

The Merck Zetia savings card is available for commercially insured patients and can reduce brand-name Zetia copays. Given that generic ezetimibe is already $9, $15 cash, the savings card is most useful for patients whose insurance covers brand Zetia but with a high copay. It does not apply to government-insured patients (MassHealth, Medicare, Medicaid).

The HealthRX Cost Decision Framework for ezetimibe in Massachusetts works as follows: patients with MassHealth should pursue PA first; uninsured or underinsured patients with income above Medicaid limits should use a GoodRx coupon at a warehouse club or Cost Plus Drugs; commercially insured patients should verify their formulary tier before filling and request generic substitution if brand Zetia is prescribed.

Is Compounded Ezetimibe Legal in Massachusetts?

Compounded ezetimibe is legal in Massachusetts when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies and permits compounding of drugs that are not commercially available in the needed form or that require a patient-specific modification [6].

Ezetimibe is commercially available as a 10 mg oral tablet, which means a 503A pharmacy cannot compound an identical duplicate solely for cost reasons under strict federal interpretation. In practice, many compounding pharmacies prepare ezetimibe in combination with other agents (for example, ezetimibe plus berberine, or ezetimibe in a unique dose strength not commercially available) which may satisfy the non-duplication requirement [6].

The Massachusetts Board of Registration in Pharmacy licenses and inspects 503A compounding pharmacies. Patients should verify that any compounding pharmacy they use holds a current Massachusetts license. The board's public license verification tool is available on the Massachusetts government website.

503B outsourcing facilities, which compound sterile products in bulk without patient-specific prescriptions, are not relevant to ezetimibe since it is an oral tablet. Oral solid dosage forms from 503A pharmacies require individual prescriptions.

From a safety standpoint, compounded ezetimibe has not been studied in the same rigorous trials as the FDA-approved product. The absorption characteristics and bioequivalence of compounded formulations have not been independently verified in published literature. Prescribers and patients should weigh this uncertainty against cost savings, particularly for patients with established ASCVD where consistent LDL lowering is well-supported by evidence [3].

Can I Get Ezetimibe via Telehealth in Massachusetts?

Telehealth prescribing of ezetimibe is fully legal in Massachusetts. A Massachusetts-licensed prescriber can evaluate a patient via audio-video telehealth, review lipid panel results, and issue an ezetimibe prescription without an in-person visit.

Massachusetts law requires that a valid prescriber-patient relationship exist before controlled substances can be prescribed via telehealth, but ezetimibe is a non-controlled Schedule-exempt medication [7]. No DEA registration or in-person examination is legally required to initiate ezetimibe therapy via telehealth in this state.

HealthRX and other telehealth platforms operating in Massachusetts must ensure their prescribers hold a current Massachusetts medical license or nurse practitioner license with prescriptive authority. The prescriber must conduct a clinically appropriate evaluation, which typically includes reviewing recent lipid panel values (within 12 months), assessing ASCVD risk using the 10-year Pooled Cohort Equations, and screening for contraindications such as pregnancy or active liver disease.

Ezetimibe is Pregnancy Category C (now described under the 2015 FDA Pregnancy and Lactation Labeling Rule as having insufficient human data) and should be discontinued when pregnancy is confirmed [1]. This is a relevant screening point in telehealth consultations.

Lipid panels can be ordered through direct-to-consumer lab services (Quest Diagnostics, LabCorp, or Everly Health) without requiring a prior in-person visit, making the full workflow from consultation to prescription fully remote for most Massachusetts patients.

How Does Ezetimibe Work and What Does the Evidence Show?

Ezetimibe selectively inhibits NPC1L1, a transporter protein responsible for approximately 50% of intestinal cholesterol absorption. It does not affect bile acid synthesis, making it mechanistically distinct from statins, bile acid sequestrants, and PCSK9 inhibitors [2].

Used as monotherapy, ezetimibe lowers LDL-C by approximately 18 to 20% from baseline. Combined with a moderate-intensity statin (for example, atorvastatin 20 mg), it can achieve an additional 15 to 20% LDL-C reduction beyond the statin alone, according to data summarized in the ACC/AHA guideline [4].

IMPROVE-IT (N=18,144) remains the landmark outcomes trial. Patients with recent acute coronary syndrome were randomized to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At 7-year follow-up, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm. The primary endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the combination group versus 34.7% of the placebo group (HR 0.936, P<0.001) [3]. The absolute risk reduction of 2.0 percentage points translates to a number needed to treat of 50 over 7 years.

A 2016 Cochrane review of ezetimibe for the prevention of cardiovascular disease and all-cause mortality (examining data from 26,714 participants across multiple trials) concluded that ezetimibe modestly reduces LDL-C and cardiovascular events when added to statin therapy, consistent with IMPROVE-IT findings [8].

The SHARP trial (N=9,270), published in The Lancet in 2011, evaluated ezetimibe plus simvastatin versus placebo in patients with chronic kidney disease and demonstrated a 17% proportional reduction in major atherosclerotic events (RR 0.83 to 95% CI 0.74, 0.94, P<0.001) [9]. This finding extended the evidence base for ezetimibe to a population in which statins are sometimes less effective or poorly tolerated.

Safety data from IMPROVE-IT and post-marketing surveillance show no significant increase in liver enzyme elevations, myopathy, or cancer incidence compared to placebo [3]. Ezetimibe does not require liver function monitoring after initiation under current FDA labeling [1].

Ezetimibe Dosing and Administration in Massachusetts Clinical Practice

The standard approved dose is ezetimibe 10 mg once daily, taken with or without food, at any time of day. No dose adjustment is required for renal impairment, mild hepatic impairment, or age. Ezetimibe is not recommended in patients with moderate to severe hepatic impairment [1].

When combined with a statin, ezetimibe can be taken at the same time or at a different time. If co-administered with a bile acid sequestrant (cholestyramine, colesevelam), ezetimibe should be taken at least 2 hours before or 4 hours after the sequestrant, because sequestrants reduce ezetimibe absorption [1].

The fixed-dose combination tablet ezetimibe/simvastatin (Vytorin, and its generics) is available in four strengths: 10/10, 10/20, 10/40, and 10/80 mg. The 10/80 combination is rarely used due to simvastatin 80 mg's higher myopathy risk, which the FDA flagged in a 2011 drug safety communication [10]. Prescribers in Massachusetts should be aware of this restriction before initiating high-dose simvastatin combinations.

The 2018 ACC/AHA guideline authors stated directly: "Ezetimibe is a safe, well-tolerated agent that, when added to maximally tolerated statin therapy, further reduces LDL-C and improves cardiovascular outcomes in patients with ASCVD" [4]. This language supports its role as a cost-effective second agent before escalating to the significantly more expensive PCSK9 inhibitors (evolocumab, alirocumab), which carry list prices above $500 per month and require separate PA processes through MassHealth and commercial insurers.

Ezetimibe vs. PCSK9 Inhibitors: The Cost-Effectiveness Argument

Given generic ezetimibe's $9, $15 monthly price in Massachusetts, most lipid guidelines recommend it as the first add-on to statin therapy before considering PCSK9 inhibitors. The ACC Expert Consensus Decision Pathway for PCSK9 Inhibitors (2017) explicitly recommends confirming ezetimibe use and LDL-C response before initiating a PCSK9 inhibitor [11].

PCSK9 inhibitors evolocumab (Repatha) and alirocumab (Praluent) reduce LDL-C by 50 to 60% beyond statin therapy, compared to 15 to 20% for ezetimibe [4]. For patients whose LDL-C remains above 70 mg/dL despite statin plus ezetimibe, a PCSK9 inhibitor may be warranted. But the incremental cost-effectiveness ratio of PCSK9 inhibitors has been estimated at $268,000, $450,000 per QALY at list price, well above conventional $100,000/QALY thresholds [12]. Ezetimibe at $9, $15/month occupies a very different cost-effectiveness position.

For Massachusetts patients with ASCVD who cannot afford PCSK9 inhibitors even after PA approval, ezetimibe represents a proven, inexpensive alternative that reduces cardiovascular events with a 7-year NNT of 50 in the IMPROVE-IT population [3].

How to Get an Ezetimibe Prescription Through HealthRX

Massachusetts residents can request an ezetimibe evaluation through HealthRX's telehealth platform. The clinical intake collects a recent lipid panel, current statin dose, ASCVD history, and medication list. A licensed Massachusetts prescriber reviews the intake within 24 hours, conducts a video or asynchronous consultation, and issues the prescription electronically to the patient's preferred pharmacy.

Prescriptions can be sent to any Massachusetts pharmacy or to a mail-order service. Patients can request the prescription be sent to Cost Plus Drugs or a local warehouse club to minimize out-of-pocket cost. For patients with MassHealth, HealthRX prescribers can complete the prior authorization form at the time of consultation, reducing the typical PA processing time.

Patients who qualify for compounded ezetimibe (for example, those who need a dose combination not commercially available) can be referred to a licensed Massachusetts 503A compounding pharmacy through the HealthRX network.

The standard monitoring recommendation after starting ezetimibe is a fasting lipid panel at 4 to 12 weeks post-initiation to assess LDL-C response, consistent with ACC/AHA guideline monitoring intervals [4]. Telehealth follow-up for lab review is available within the HealthRX platform at no additional consultation fee for established patients.